Michigan Patent of the Month – June 2024

Immunolight, LLC, a biotech company focused on fighting solid tumors, has been granted a patent for their X-ray psoralen activated cancer therapy treatment.

This represents a significant leap forward in the treatment of cell proliferation disorders using advanced photoactivation technology. This innovative approach combines the use of phosphors capable of emitting ultraviolet or visible light with a potent photoactivatable drug, administered directly into diseased sites within the human or animal body.

At the heart of this method lies the synergy between two critical components: the phosphors embedded in a pharmaceutical carrier and the photoactivatable drug designed to intercalate into DNA. By injecting these agents into the diseased site and subsequently applying controlled doses of x-rays, Immunolight’s system triggers the emission of ultraviolet or visible light directly at the targeted cells. This light activation process enhances the cytotoxic effects of the photoactivatable drug, inducing significant cell death within the diseased area.

This approach offers several key advantages over traditional treatments. Firstly, it allows for precise targeting of diseased tissues while minimizing damage to surrounding healthy cells. Secondly, the use of phosphors that emit light upon x-ray exposure ensures a controlled and localized activation of the photoactivatable drug, optimizing therapeutic outcomes. Moreover, the method’s ability to induce apoptosis in targeted cells through DNA intercalation presents a promising avenue for treating various cancers and other cell proliferation disorders.

Immunolight’s innovation builds upon the established efficacy of psoralens in cancer therapy, leveraging their potent photochemical properties to achieve therapeutic goals with greater precision and effectiveness. The method not only aims to reduce tumor volumes significantly but also holds promise for inducing long-term clinical responses by enhancing immunogenicity through apoptotic cell uptake and immune system modulation.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Recent Posts